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ABSTRACT
We recently found that trastuzumab benefit may be lower in a small subset of 
early breast cancer (BC) patients (pts) with tumors expressing high levels of both 
hormonal receptors (HRs), i.e. triple positive (TP). To better investigate the role of 
HRs in HER2 positive BC, we retrospectively identified 872 TP BC pts treated with 
adjuvant chemotherapy alone (cohort A-366 pts), or plus trastuzumab (cohort B-506 
pts). Relapse-free-survival (RFS) and breast-cancer-specific-survival (BCSS) were 
evaluated. Trastuzumab improved RFS and BCSS in all the subsets analyzed, but the 
effect on BCSS in tumors expressing both HRs in >30% of cells (TP30), and even on 
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RFS in tumors with both HRs expressed in >50% of cells (TP50) was not significant. 
Distinct patterns of relapse were observed in TP50 and no-TP50 tumors, the former 
showing low and constant risk in the first 5 years, a late increase beyond 5 years and 
modest trastuzumab effect. Trastuzumab effect tended to disappear in pts whose 
tumors expressed ER in >50% of cells. Multivariate analysis of RFS confirmed a 
significant interaction between trastuzumab and ER expression, with benefit confined 
to pts whose tumors expressed ER in ≤50% of cells.
Our data suggest that the pattern of relapse of TP tumors with high HRs is similar 
to that of “luminal”, HER2 negative tumors, without clear benefit from adjuvant 
trastuzumab, which remains the standard treatment even in TP tumors. Confirmatory 
findings on the extent to which quantitative expression of HRs may impact clinical 
behavior of HER2 positive BC are warranted.
INTRODUCTION
Approximately 25% of breast cancers overexpress the 
human epidermal growth factor receptor 2 (HER-2) and have 
an aggressive clinical behaviour [1]. About half of HER-2 
positive breast cancer also express hormone receptors (HRs), 
even if HER-2 positive tumors often, though not always, 
express HRs at lower levels compared with HR positive/
HER-2 negative tumors [2]. Overall, the use of trastuzumab 
combined with chemotherapy has dramatically improved 
prognosis in all stages of HER-2 positive breast cancer 
[3-5]. There has been a general consensus in fact, that the 
HER-2 oncogene, when overexpressed, is the dominant 
driver of breast cancer biology, regardless of HR status [6], 
and current guidelines support the use of anti-HER-2 agents 
combined with chemotherapy in all the disease settings. 
Even though treatment with HER-2 targeted agents in all 
stages of HER-2 positive breast cancer has shown benefit 
independently on HR status, it is now being increasingly 
clear that the magnitude of such benefit may differ by HR 
status. In the adjuvant setting recent reports of outcomes 
by tumor subtype demonstrated that HR positive/HER-
2 positive tumors show usually different behavior and 
response to therapy, as well as distinct timing and pattern 
of relapse in comparison to HR negative/HER-2 positive 
tumors [6-10]. Yet, no data on outcome are specifically 
reported on tumors expressing HER-2 and both HRs, i.e., 
estrogen receptor (ER) and progesterone receptor (PgR). 
The subset of “triple positive” (TP: ER/PgR/HER-2 positive) 
tumors might represent a distinct entity with a particularly 
favourable prognosis, and the combination of chemotherapy, 
HER-2 blockade and endocrine treatment, in some instances, 
might be considered an overtreatment. Thus far, only few 
studies evaluated the degree of HRs expression in HER-2 
positive disease, together with its influence on treatment 
efficacy and prognosis [11, 12] and, to our knowledge, no 
study has focused on TP treatment outcomes.
In a recent work we analyzed data from a large 
historic cohort of HER-2 positive early breast cancer 
patients treated with chemotherapy alone or with 
sequential trastuzumab at various Italian cancer centres 
between 1998 and 2011. Results were in key with a clear 
benefit of adding trastuzumab to adjuvant chemotherapy 
in all breast cancer subsets, including TP tumors, with the 
unique exception of a small cohort of tumors expressing 
very high levels (≥50%) of both HRs (TP50) [13].
In order to better define and interpret the outcome 
of adjuvant treatment specifically in this relevant subset, 
we expanded our initial cohort of TP, early breast cancer 
patients treated with chemotherapy with or without 
trastuzumab in the routine clinical practice by adding data 
collected in nineteen Italian oncologic centres.
RESULTS
Patient and tumor characteristics
Overall, we retrospectively identified 872 
consecutive, TP positive, early breast cancer patients 
treated in routine clinical practice in nineteen Italian 
cancer centers between January 1998 and December 2011.
Main baseline patient and tumor characteristics 
are reported in Table 1. Overall, the HER-2 gene was 
overexpressed (3+) in 716 (82.1%) and amplified in 156 
tumors (17.9%). Among the patients enrolled, 366 (41.9%) 
and 506 (58%) patients received adjuvant chemotherapy 
without (cohort A) and with trastuzumab (cohort B), 
respectively. Median age and menopausal status were well 
balanced between the two cohorts. Conversely, patients in 
cohort B had more frequently higher stage, grade 3 and 
high Ki67 tumors, compared with those in cohort A.
Adjuvant treatment
Data on adjuvant treatments are reported in 
Table 2. Overall, among 872 enrolled patients, 34.4% 
patients received anthracycline-based, 8.4% taxane-
based, 44.8% anthracycline+taxane-based, and 12.4% 
anthracycline-taxane-free chemotherapy. Anthracycline-
based regimens were more common in cohort A (51.4%) 
than in cohort B (22.1%). Conversely, more patients 
received anthracycline+taxanes-based regimens in cohort 
B (62.5%), compared to cohort A (20.2%). A comparable 
proportion of patients in both cohorts received 6 or more 
cycles of adjuvant chemotherapy (71.3% and 78.3% in 
cohort A and B, respectively). Trastuzumab was given 
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Table 1: Descriptive characteristics of the study population (N=872)
Characteristic N (%) p
Cohort A (366 pts) Cohort B (506 pts)
Age (years)
  Median 52 53 0.54
  Range (29-85) (26-79)
Menopausal status
  Pre 167 (45.6) 220 (43.5) 0.53
  Post 199 (54.4) 286 (56.5)
Histology
  Ductal 311 (84.9) 460 (90.9) 0.006
  Lobular 28 (7.7) 24 (4.7)
  Other 27 (7.4) 22 (4.4)
Tumor size
  T1 199 (54.4) 335 (66.2) 0.005
  T2 155 (42.3) 157 (31)
  T3 8 (2.2) 9 (1.8)
  T4 4 (1.1) 5 (1)
Nodal status
  N0 151 (41.3) 250 (49.4) 0.02
  N1 118 (32.2) 162 (32)
  N2 58 (15.8) 61 (12.1)
  N3 39 (10.7) 33 (6.5)
Clinical stage
  I 111 (30.3) 201 (39.7) <0.0001
  II 146 (39.9) 211 (41.7)
  III 109 (29.8) 94 (18.6)
Grading
  G1 15 (4.1) 17 (3.4) 0.001
  G2 167 (45.6) 181 (35.8)
  G3 163 (44.5) 292 (57.7)
  Unknown 21 (5.7) 16 (3.2)
Ki67
  ≤14% 72 (19.7) 83 (16.4) <0.0001
  >14% 262 (71.6) 407 (80.4)
  Unknown 32 (8.7) 16 (3.2)
Multifocality
  Unifocal 240 (65.6) 369 (72.9) 0.04
  Multifocal 88 (24) 103 (20.4)
  Unknown 38 (10.4) 34 (6.7)
(Continued )
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sequentially in 28% of the patients, and concomitantly 
with chemotherapy in 72% of the patients. The majority 
of patients (93.2%) received the three-weekly schedule 
of trastuzumab (8 mg/kg loading dose, followed by three-
weekly doses of 6 mg/kg), with a median duration of 
52 weeks (range, 6-75). All but 70 patients (8%) started 
standard adjuvant hormonal therapy upon completion of 
chemotherapy. Radiotherapy was given when indicated, 
according to the Institutional guidelines.
Survival analysis
The median follow up for the whole patient 
series was 78 months (95% CI, 74 to 82), being 123 
months (95% CI, 118 to 128) in cohort A and 62 months 
(95% CI, 59 to 65) in cohort B. Overall, we observed 
194 recurrences, 139 in cohort A and 55 in cohort B. 
Kaplan-Meier estimates of RFS and BCSS according to 
cohort of treatment in the overall population are shown 
in Figure 1.
To study the effect of different cutoffs of HRs 
expression in TP tumors we defined a TP30 (both ER and 
PgR expressed in >30% of tumor cells) and a TP50 (both 
ER and PgR expressed in >50% of tumor cells) populations. 
Estimates of 3- and 5-year RFS and BCSS in the overall, the 
TP30 and the TP50 populations are summarized in Table 3. 
Adjuvant trastuzumab (cohort B) was associated with a RFS 
and BCSS benefit in the overall study population. In addition, 
no differences were observed in outcomes depending on 
treatment schedule (weekly or three-weekly, concomitant or 
sequential with chemotherapy), and use of regimens including 
anthracyclines and taxanes (data available upon request). 
However, the BCSS advantage in the TP30 populations and 
both the RFS and BCSS advantages in the TP50 populations 
failed to reach statistical significance (Table 3). To further 
explore the potential effect of having both ER and PgR 
expressed in more than 50% of tumor cells, we compared 
the annualized hazards of RFS for cohort A and B patients 
in the overall, TP50, and no-TP50 (i.e. remainder patients, 
whose tumor do not have simultaneous expression of ER and 
Characteristic N (%) p
Cohort A (366 pts) Cohort B (506 pts)
HER2 status
  Overexpressed (3+) 313 (85.5) 403 (79.6)
0.02
  Amplified 53 (14.5) 103 (20.4)
Hormone receptor status
TP ER 1-30 tumors 55 (15) 49 (9.8)
0.001
TP ER 31-50 tumors 53 (14.5) 42 (8.3)
TP ER 51-70 tumors 68 (18.6) 103 (20.3)
TP ER 71-100 tumors 190 (51.9) 312 (61.6)
TP PgR 1-30 tumors 134 (36.2) 184 (36.4)
0.99
TP PgR 31-50 tumors 60 (16.0) 83 (16.4)
TP PgR 51-70 tumors 69 (18.7) 95 (18.7)
TP PgR 71-100 tumors 103 (29.1) 144 (28.5)
TP50 147 (40.2) 223 (44.1)
0.25No TP 50 219 (59.8) 283 (55.9)
TP30 214 (58.5) 314 (62.1)
0.29
No TP30 152 (41.5) 192 (37.9)
Abbreviations: Pts, patients; TP ER 1-30, triple positive tumors (HER2/ER/PgR-positive) with ER staining in 1-30% 
tumor cells; TP ER 31-50, TP tumors with ER staining in 31-50% tumor cells; TP ER 51-70, TP tumors with ER staining 
in 51-70% tumor cells; TP ER 71-100, TP tumors with ER staining in 71-100% tumor cells; TP PgR 1-30, TP tumors with 
PgR staining in 1-30% tumor cells; TP PgR 31-50, TP tumors with PgR staining in 31-50% tumor cells; TP PgR 51-70, TP 
tumors with PgR staining in 51-70% tumor cells; TP PgR 71-100, TP tumors with PgR staining in 71-100% tumor cells; 
TP30, TP tumors with both ER and PgR staining in more than 30% tumor cells; TP50, TP tumors with both ER and PgR 
staining in more than 50% tumor cells.
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Table 2: Treatment administered to the study population (N=872).
Characteristics N (%) p
Cohort A (366 pts) Cohort B (506 pts)
Surgery
  Conservative 214 (58.5) 341 (67.4)
0.007 
  Radical 152 (41.5) 165 (32.6)
Chemotherapy regimens
  Anthracyclines-based 188 (51.4) 112 (22.1)
<0.0001 
  Taxanes-based 13 (3.6) 61 (12.1)
  Anthracyclines and Taxanes-based 74 (20.2) 316 (62.5)
  No anthracyclines and No taxanes–based 91 (24.9) 17 (3.4)
Cycles of chemotherapy
  <6 64 (17.5) 78 (15.4)
0.24   ≥6 261 (71.3) 396 (78.3)
  Unknown 41 (11.2) 32 (6.3)
Radiotherapy
  Yes 235 (64.2) 373 (73.7)
0.003 
  Not 131 (35.8) 133 (26.3)
Hormonal therapy
  Yes 332 (90.7) 470 (92.9)
0.24 
  Not 34 (9.3) 36 (7.1)
Abbreviations: Pts, patients
Figure 1: Relapse-free survival (1) and breast cancer specific survival (2) in the overall study population (N=872) 
according to cohort. Abbreviations: RFS, relapse free survival; BCSS, breast cancer specific survival. Cohort A: red line; Cohort B: 
blue line.
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Figure 2: Hazard rate of recurrence for the overall study population (panel A) and in patients with ER and PgR 
staining in more than 50% of tumour cells (TP50, panel B) and other patients (noTP50, panel C). Cohort A: red line; 
Cohort B: blue line.
Table 3: Summary of 3 and 5-year relapse-free survival (RFS) and breast cancer specific survival (BCSS) 
comparisons between Cohort A and Cohort B according to study population
Population Number 3-year 
RFS
5-year 
RFS
HR P 3-year 
BCSS
5-year 
BCSS
HR P
Overall
  Cohort A 366 87.0 78.2 0.48 <0.0001 96.3 93.9 0.39 0.001
  Cohort B 506 95.6 89.9 (0.35-
0.67)
99.3 97.4 (0.21-
0.73)
TP30
  Cohort A 214 89.4 81.4 0.60 0.02 97.1 96.6 0.63 0.26
  Cohort B 314 95.6 90.7 (0.39-0.93) 99.3 97.5
(0.28-
1.43)
TP50
  Cohort A 147 90.3 83.7 0.64 0.09 95.7 95.7 0.50 0.16
  Cohort B 223 95.7 90.6 (0.38-
1.07)
100 97.4 (0.19-1.35)
Abbreviations: Pts, patients; TP 30, triple positive tumors (HER2/ER/PgR-positive) with ER and PgR staining > 30% tumor 
cells; TP 50, triple positive tumors (HER2/ER/PgR-positive) with ER and PgR staining > 50% tumor cells; HR, hazard ratio.
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PgR in >50% of tumor cells) populations (Figure 2, panels 
a, b and c, respectively). In the no-TP50 population, relapse 
events tended to occur during the initial 5 years at a constant 
rate and the effect of trastuzumab in reducing relapse events 
appeared constant over this time-interval (Figure 2, panel c). 
Conversely, in TP50 patients (Figure 2, panel b) a clear effect 
of trastuzumab could not be observed and in both cohorts 
the hazards of relapse tended to increase slightly beyond 5 
years of follow-up. We performed a STEPP analysis to relate 
increasing percentages of cells staining positively for ER 
(Figure 3, panel a) and for PgR (Figure 3, panel b) with the 
risk of relapsing at 5 years according to cohort. For ER, we 
observed a clear reduction in such risk beyond 50% of tumor 
cells staining positively, whereas no such effect was seen for 
increasing PgR expression. At multivariate analysis factors 
related to increased risk of relapse at 5 years were presence of 
multifocality, high tumor grade, advanced stage at diagnosis, 
no adjuvant endocrine therapy, no adjuvant trastuzumab and 
ER≤50%. Since we found a significant 2X2 interaction of 
ER expression with the effect of trastuzumab (p = 0.01), in 
the final model we report the effect of trastuzumab across 
the two strata of the ER50 variable, together with the other 
variables independently associated with RFS (Table 4). In the 
ER>50 stratum, trastuzumab showed no significant effect on 
5-year RFS.
DISCUSSION
In this retrospective analysis, we sought to expand 
our previous observation that in patients with operable 
HER2-positive breast cancer, high co-expression of both 
the ER and PgR (“triple-positivity”-TP) could mitigate 
the effect of trastuzumab administered with adjuvant 
chemotherapy [13]. In fact, in the RETROHER study, 
we found little benefit of adjuvant trastuzumab in 163 
women with HER2-positive operable breast cancer whose 
tumors were positive for both the ER and PgR in ≥50% 
of tumor cells. We thought that this initial observation 
deserved further investigation. To better study the 
influence of degree and pattern of HRs expression on 
clinical behavior and trastuzumab efficacy, we recruited 
872 patients with TP breast cancer selected on the basis 
of a HER2-positive status and simultaneous expression of 
both ER and PgR in at least 1% of the tumor cells. Our 
first finding was that hazard ratios for RFS and BCSS 
were consistently in favor of trastuzumab in the overall, 
TP30 and TP50 populations, although differences failed 
to achieve statistical significance for BCSS in the TP30, 
and for RFS and BCSS in the TP50 populations. Five-
year absolute, trastuzumab-related RFS gains were 9.5% 
and 6.9% for TP30 and TP50 patients respectively, with 
Figure 3: Stepp analysis of the effect on ER (Panel A) and PgR (Panel B) expression on the hazard of relapse in the two 
cohorts. Abbreviations: ER, estrogen receptor ; PgR, progesterone receptor; RFS, relapse free survival.
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apparently no effect on BCSS (0.9% and 1.7% for TP30 
and TP50 patients, respectively). Corresponding figures 
in the overall population were 11.7% and 3.4% for RFS 
and BCSS, respectively (Table 3). A second finding of 
our study was that the annualized hazard of relapse in 
TP50 patients differs profoundly from that of patients 
whose tumors do not have simultaneous expression of ER 
and PgR in >50% of tumor cells (No-TP50) (Figure 2). 
Furthermore, in this latter group of patients, a favorable 
effect of trastuzumab was seen early and persisted for 
4-6 years from surgery. Conversely, for TP50 patients 
the annualized hazard of disease relapse tended to remain 
low and constant for about 6 years from surgery and to 
increase thereafter, with no clear pattern regarding the 
effect of trastuzumab. The third finding of our study 
was that expression of the ER in >50% of tumor cells 
was associated with a potential reduction in the effect 
of trastuzumab on RFS, and a statistically significant 
interaction could be demonstrated at the multivariate 
analysis (Table 4). Taken together, these results suggest 
that trastuzumab added to chemotherapy must remain a 
standard of care in patients with HER2 positive tumors, 
regardless hormone receptor status. However, quantitative 
expression of HRs may influence the clinical behavior of 
HER2-positive breast cancer, with potentially relevant 
implications in the estimation of risk and timing of relapse 
and, finally, on treatment choices.
In the interpretation of these results we must 
consider obvious biases that are related to the 
retrospective methodology that we used. Cohort A and 
B were sequential and not parallel, resulting in median 
follow-up in cohort A being twice as long as that of 
patients in cohort B. Consequently, more disease relapses 
and breast cancer deaths may have occurred in cohort 
A just because of longer observation time. Although 
HER2-positivity confers early metastatic potential, 
long term follow-up of the adjuvant HERA trial shows 
events beyond 5 years in patients receiving trastuzumab 
[14]. Therefore, we could not exclude that 60 months of 
median follow-up of cohort B of our study is insufficient 
to capture all the events.
Furthermore, because of the non-randomized 
design, some imbalances were seen in cohort A and B 
with respect to histopathological features. Although more 
frequently high-stage, high-grade and highly proliferating, 
tumors in cohort B were also more frequently high in 
HRs expression than patients in cohort A (Table 1). This 
is another factor that may have biased the comparison of 
outcomes between the two cohorts.
Finally, and perhaps most importantly, the ER/
PgR expression level is just a surrogate for molecular 
subtyping, and quantitative analysis of ER and PgR 
status was not centralized, but extracted from the medical 
charts of the patients at each participating Institution. 
As a consequence, inter-laboratory variability and bias 
cannot be excluded and should be taken into account in 
interpreting our results [15].
Several adjunctive variables, not investigated in the 
present study, such as the level of stromal Lymphocyte 
Tumor Infiltration (sTIL) and PIK3CA mutations, 
EGFR or PTEN expression, along with distinct intrinsic 
molecularly-defined subtypes, may have influenced 
Table 4: Multivariate logistic regression model of factors impacting survival outcomes in the study population
Factors 5 year RFS 
OR (95%CI) P-value
Multifocality
Yes vs No 1.96(1.17-3.28) 0.01
Grading
3 vs 1 - 2 2.26(1.36-3.75) 0.002
Stage
III vs I-II 3.59(2.20-5.85) <0.0001
Hormonal therapy
No vs Yes 2.88(1. 53-6.14) 0.006
aTrastuzumab therapy in ER≤50%
No vs Yes 4.33 (1.78-10.55) 0.001
aTrastuzumab therapy in ER50
No vs Yes 1.16 (0.70-1.93) 0.57
Abbreviations: CI, confidence interval; OR, Odds ratio; RFS, Relapse-Free Survival; ER50, TP tumors with ER staining in 
more than 50% tumor cells
aER*Trastuzumab therapy, pINTERACTION =0.01
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outcomes [16-21]. Despite the numerous potential biases, 
we believe in the biological and clinical plausibility of 
our results and in their potential implications for further 
research in this area.
In HER2-negative breast cancer, a number of 
studies have confirmed that late disease-related events 
are common in HRs positive patients [22]. This translates 
into a time-dependent hazard ratio for HRs positive vs 
HRs negative tumors [23, 24]. This same phenomenon 
was recently observed in women enrolled in the adjuvant 
Tykerb Evaluation after Chemotherapy (TEACH) clinical 
trial [25], where patients with HER2 positive operable 
breast cancer not receiving adjuvant trastuzumab were 
randomized to adjuvant lapatinib or observation at a 
median time from diagnosis of 70 months. A recent report 
focusing on patients assigned to the placebo arm revealed 
that HR status (positive vs negative) had a time-varying 
effect on the hazard of disease relapse [26]. HRs positive 
tumors showed a slowly decreasing hazard compared 
with HRs negative tumors, which showed a higher and 
more rapidly declining hazard of disease-relapse during 
follow-up. At approximately 6 years, the two annualized 
hazard curves tended to cross. This observation confirms 
that HR status (positive vs negative) may influence clinical 
behavior also in HER2-positive breast cancer.
Since high expression of ER and PgR is regarded 
as a proxy for an “endocrine-responsive” behavior we 
decided to focus our analysis on TP tumors [27]. In line 
with the previously mentioned results, we could show 
that, within HER2-positive/HRs positive breast cancers, 
the expression of either or both ER and PgR in >50% of 
tumor cells identifies entities that behave like “endocrine-
responsive” tumors. Additionally, STEPP analysis could 
show a sharp reduction in the effect of trastuzumab in 
tumors expressing the ER in more than 50% of the cells.
An intriguing retrospective evaluation of eight 
predictive genes associated with HER2 or ER in the 
NSABP-B31 trial showed that high-levels of ESR1 mRNA 
expression may be associated to low trastuzumab benefit 
[28]. We may hypothesize that the high ER expression 
level in a subset of patients in the present study might be 
representative of the subgroup with higher ESR1 mRNA 
expression.
Conversely to widespread belief in the early 
2000s, it is now widely recognized that HER2 positive 
tumors are not homogeneous and that HRs co-
expression represents a robust biomarker of both the 
clinical behavior and the effect of anti-HER2 treatments 
[29]. This latter factor emerged clearly in the neo-
adjuvant setting, when results of the NEO-ALTTO 
and NEO-SPHERE trials, evaluating neoadjuvant 
taxanes with anti HER2 treatments in HER2-positive 
patients, showed a clear reduction in pCR when the 
tumor co-expressed HRs, mirrored by very high pCR 
in HER2-positive/HRs negative tumors [30, 31]. 
Further observations from retrospective studies in 
the metastatic and neoadjuvant setting also suggested 
a potential relationship between degree of HRs 
expression and response to trastuzumab treatment, with 
reduced activity in patients with high-expression [11, 
12]. Additionally, while predicting shorter disease-free 
survival in HER2-positive/HRs negative tumors, failing 
to achieve a pCR following neoadjuvant treatment 
does not preclude favorable long-term outcomes in 
HER2-positive/HRs positive tumors [32]. This effect 
on outcome is clearly due to the fact that, despite 
being acknowledged as a predictor of resistance to 
endocrine therapy, in the context of HER2 inhibition, 
HER2-positive/HRs positive tumors can partially 
recover endocrine-responsiveness [33-35]. Indeed, 
a retrospective study confirmed long progression-
free survival in women assigned to trastuzumab and 
maintenance endocrine therapy after stable disease 
or tumor response to first-line chemotherapy and 
trastuzumab [11]. The biology behind HER2-positive 
breast cancer provides explanations for this clinical 
diversity, calling into cross-talk between the HER2 and 
HRs pathways [29, 32, 36]. Traditionally, this cross-
talk has been considered unidirectional, where aberrant 
HER2 function could provide escape to endocrine 
therapy. Recent data suggest bidirectional and dynamic 
cross-talk, where also the HRs pathway could provide 
escape to HER2-inhibition. A neoadjuvant study 
of HER2 targeting agents and endocrine therapy 
showed an increase in pCR when both treatments are 
administered concomitantly, thus confirming preclinical 
models [37]. Biological diversity has been recently 
further clarified in the most comprehensive molecular 
characterization of breast cancer, which clearly shows 
that two distinct HER2 positive breast cancer exist 
[38]. One is the HER2-enriched mRNA subtype, 
which is characterized by increased expression of 
tyrosine-kinase receptor like FGFR4, EGFR, and of 
genes mapping on the HER2 amplicon. The other is 
the luminal mRNA subtype positive, with increased 
expression of luminal genes like BCL2, GATA3 and 
ESR1. One major phenotypical difference between 
these two subgroups is the expression of hormone 
receptors, which is rare in the former, and frequent in 
the latter subtype. Unfortunately, immunohistochemical 
surrogates of these two distinct biological entities are 
barely obtainable in the clinic, being the mere positivity 
for either the ER or PgR a definition that could 
encompass both subtypes. Therefore, additional markers 
of the “luminal/HER2-positive” phenotype are awaited 
to better exploit biological diversity in the clinic. A 
recent report from Neoadjuvant Breast Symphony trial 
compared a multigene classifier (Blue-Print 80-gene 
assay) to conventional IHC/FISH to predict pCR to 
chemotherapy plus HER2 block. The Blue-Print (BP) 
assay re-classified more than 1 over 5 tumors, and the 
group with the biggest change was the TP group, where 
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the BP-defined “luminal” subgroup showed the lower 
pCR to trastuzumab (11%), compared to that of the BP-
defined HER2 (45%); the pCR increased with double-
block including pertuzumab [39].
Overall, we provide evidence that the clinical 
behavior of TP breast cancer could depend upon 
quantitative expression of HRs, with highly co-expressing 
tumors behaving in a luminal fashion, i.e., low but 
constant hazard of relapse in the initial 5 years after 
surgery, and possibly, slow increase thereafter resulting 
in late recurrences. Furthermore, increasing expression 
of ER seems to be associated with reduced trastuzumab 
effect. We believe, however, that future studies should 
try to address this issue with appropriate methodology 
because of the potential implications on treatment tailoring 
according to the biological diversity of HER2-positive 
breast cancer.
MATERIALS AND METHODS
Our cohort included patients with early TP tumors 
routinely treated in the adjuvant setting in nineteen Italian 
oncologic centres over a period of thirteen years (from 
1998 to 2011). Written informed consent was obtained 
from all patients. Information on demographics, clinical, 
histopathological and molecular features, adjuvant 
therapies and outcomes were retrieved from the patients’ 
medical records. Anonymized data were entered into an 
ad hoc database. Two cohorts were analyzed: patients who 
received adjuvant chemotherapy without trastuzumab, 
mostly until 2005 (cohort A), and patients who received 
adjuvant chemotherapy followed by or combined with 
trastuzumab (cohort B) since 2006, when adjuvant 
trastuzumab was approved in Italy. Endocrine treatment 
and radiotherapy were sequentially given whenever 
indicated according to standard guidelines.
Pathology assessment was performed on surgical 
specimens by the pathologists at the participating centers 
as per National standards. ER and PgR status were 
determined at each center by immunohistochemistry 
according to local standards. Positivity was considered 
at a cutoff of ≥1 % of tumor cells stained. Ki-67 was 
tested using the mAb MIB1 (Dako) and regarded high 
if >14 % of the cell nuclei were immunostained. HER2 
overexpression was tested using the polyclonal antibody 
A0485 (Dako), and was considered positive if grade 3+ 
staining intensity by immunohistochemistry, or grade 
2+ with gene amplification by fluorescence, silver 
or chromogenic in situ hybridization was detected. 
Definitions and cutoffs for HER2 positivity were the same 
as those used in the pivotal trastuzumab adjuvant trials. If 
missing, the molecular features were centrally evaluated 
in formalin fixed, paraffin-embedded tissue sections, 
whenever available. This study was approved by the 
institutional ethical committee of the coordinating center 
(Regina Elena National Cancer Institute of Rome) and 
satellite centers and was conducted in compliance with 
Helsinki Declaration.
Statistical analysis
Associations between categorical variables were 
tested by the Pearson Chi Square test or the Fisher Exact 
test, when appropriate. Relapse-free survival (RFS, time 
from surgery to any invasive or non-invasive breast 
cancer recurrence, either local, regional, contralateral or 
distant) and breast cancer specific survival (BCSS, time 
from surgery to death in patients who had developed 
metastatic disease) where chosen as outcome variables of 
interest. For both RFS and BCSS, patients dying without 
prior evidence of metastatic disease were censored at the 
date of their last follow-up visit. Median follow-up was 
calculated with the reverse method [40]. Kaplan-Meier 
curves of RFS and BCSS were compared by the log-rank 
test, with statistical significance set at p≤0.05. The impact 
of independent variables of interest on 5-years RFS was 
studied by univariate and multivariate logistic regression 
model. Odds Ratios are reported together with their 95% 
confidence intervals (95% C.I.). For the multivariate 
analyses we adopted a stepwise regression (forward 
selection) method by selecting significant variables upon 
univariate analysis. Enter limit and remove limit were 
p = 0.10 and p = 0.15, respectively. The annual hazard 
function, giving the risk of disease at a specified time 
conditional on remaining disease-free up until that point 
in time, was estimated by cohorts and by HR status using 
splines, with separate splines fit for the cohort and by HR 
status. The subpopulation treatment effect pattern plot 
(STEPP) analysis was performed to evaluate treatment-
effect heterogeneity when HRs expression is measured 
on a continuous scale. STEPP graphically explores the 
patterns of treatment effect across overlapping intervals 
of the HRs values [41]. The SPSS software (SPSS version 
21.0, SPSS Inc., Chicago, Illinois, USA) and R-Software 
(version 3.2.1) were used for statistical evaluations.
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